Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tvardi Therapeutics, Inc. (TVRD : NSDQ)
 
 • Company Description   
Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.67 Daily Weekly Monthly
20 Day Moving Average: 86,081 shares
Shares Outstanding: 9.36 (millions)
Market Capitalization: $212.21 (millions)
Beta: 0.20
52 Week High: $34.31
52 Week Low: $8.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.18% -16.43%
12 Week 33.05% 11.91%
Year To Date 23.46% 15.62%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3 SUGAR CREEK CTR. BLVD SUITE 525
-
SUGAR LAND,TX 77478
USA		 ph: 713-489-8654
fax: 203-567-1510		 ir@tvardi.com http://www.tvarditherapeutics.com
 
 • General Corporate Information   
Officers
Christopher Posner - President; Chief Executive Officer
Ryan Maynard - Chief Financial Officer
Martin Vogelbaum - Director
Jeffrey Ives - Director
Lisa von Moltke - Director

Peer Information
Tvardi Therapeutics, Inc. (CORR.)
Tvardi Therapeutics, Inc. (RSPI)
Tvardi Therapeutics, Inc. (CGXP)
Tvardi Therapeutics, Inc. (BGEN)
Tvardi Therapeutics, Inc. (GTBP)
Tvardi Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 140755307
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 9.36
Most Recent Split Date: 4.00 (0.33:1)
Beta: 0.20
Market Capitalization: $212.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.32 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 28.03
EPS Growth
vs. Year Ago Period: 84.04%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 20.33%
vs. Previous Quarter: 76.56%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -710.04
ROA
06/30/25 - -
03/31/25 - -79.00
12/31/24 - -103.35
Current Ratio
06/30/25 - -
03/31/25 - 32.48
12/31/24 - 11.03
Quick Ratio
06/30/25 - -
03/31/25 - 31.73
12/31/24 - 10.81
Operating Margin
06/30/25 - -
03/31/25 - -538.94
12/31/24 - -933.07
Net Margin
06/30/25 - -
03/31/25 - -595.39
12/31/24 - -992.95
Pre-Tax Margin
06/30/25 - -
03/31/25 - -600.65
12/31/24 - -998.53
Book Value
06/30/25 - -
03/31/25 - -2.59
12/31/24 - -3.02
Inventory Turnover
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.42
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©